These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 17620694)

  • 21. Tolerability of the Biken acellular pertussis vaccine in adults with or without previous vaccination against pertussis in childhood.
    Knuf M; Schmitt HJ; Mohnike K; Zepp F; Habermehl P; Kampmann C; Herden P
    Med Klin (Munich); 2004 Sep; 99(9):495-9. PubMed ID: 15372178
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Administration of tetanus, diphtheria, and acellular pertussis vaccine to parents of high-risk infants in the neonatal intensive care unit.
    Dylag AM; Shah SI
    Pediatrics; 2008 Sep; 122(3):e550-5. PubMed ID: 18762489
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Simultaneous vaccination of Chinese applicants for a United States immigrant visa.
    Hua L; Hongtao H; Shunqin W; Jinping G; Jiandong C; Zhaoliang L; Xinwen F
    Travel Med Infect Dis; 2008 May; 6(3):130-6. PubMed ID: 18486068
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Booster vaccination of toddlers with reduced antigen content diphtheria -- tetanus -- acellular pertussis vaccine.
    Nolan T; Ruff TA; Lambert SB; Buttery J; O'Grady KA; Streeton C; Hoet B; Bock HL
    Vaccine; 2009 Apr; 27(18):2410-3. PubMed ID: 19368781
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Long-term follow-up of Swedish children vaccinated with acellular pertussis vaccines at 3, 5, and 12 months of age indicates the need for a booster dose at 5 to 7 years of age.
    Gustafsson L; Hessel L; Storsaeter J; Olin P
    Pediatrics; 2006 Sep; 118(3):978-84. PubMed ID: 16950988
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Safety and immunogenicity of a combined DTPa-IPV vaccine administered as a booster from 4 years of age: a review.
    Jacquet JM; Bégué P; Grimprel E; Reinert P; Sandbu S; Silfverdal SA; Faldella G; Nolan T; Lambert S; Richmond P; Marshall H; Roberton D; Schuerman L
    Vaccine; 2006 Mar; 24(13):2440-8. PubMed ID: 16406224
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Safety and immunogenicity of a pentavalent vaccine compared with separate administration of licensed equivalent vaccines in US infants and toddlers and persistence of antibodies before a preschool booster dose: a randomized, clinical trial.
    Guerra FA; Blatter MM; Greenberg DP; Pichichero M; Noriega FR;
    Pediatrics; 2009 Jan; 123(1):301-12. PubMed ID: 19117896
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Safety of a fifth dose of diphtheria and tetanus toxoid and acellular pertussis vaccine in children experiencing extensive, local reactions to the fourth dose.
    Rennels MB; Black S; Woo EJ; Campbell S; Edwards KM
    Pediatr Infect Dis J; 2008 May; 27(5):464-5. PubMed ID: 18398385
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immunogenicity, reactogenicity, and safety of a seven-valent pneumococcal conjugate vaccine (PCV7) concurrently administered with a fully liquid DTPa-IPV-HBV-Hib combination vaccine in healthy infants.
    Olivier C; Belohradsky BH; Stojanov S; Bonnet E; Petersen G; Liese JG
    Vaccine; 2008 Jun; 26(25):3142-52. PubMed ID: 18502545
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ultrasound examination of extensive limb swelling reactions after diphtheria-tetanus-acellular pertussis or reduced-antigen content diphtheria-tetanus-acellular pertussis immunization in preschool-aged children.
    Marshall HS; Gold MS; Gent R; Quinn PJ; Piotto L; Clarke MF; Roberton DM
    Pediatrics; 2006 Oct; 118(4):1501-9. PubMed ID: 17015541
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of lowering the aluminium content of a dTpa vaccine on its immunogenicity and reactogenicity when given as a booster to adolescents.
    Theeten H; Van Damme P; Hoppenbrouwers K; Vandermeulen C; Leback E; Sokal EM; Wolter J; Schuerman L
    Vaccine; 2005 Feb; 23(12):1515-21. PubMed ID: 15670888
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Time for booster doses against whooping cough for 10-year-old children].
    Carlsson RM; Ekholm L; Gothefors L; Granström M; Trolin I; Tegnell A
    Lakartidningen; 2005 Aug 29-Sep 4; 102(35):2394-8. PubMed ID: 16184889
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Boostrix: a reduced-dose acellular pertussis vaccine for use in adolescents and adults.
    Li WC; Wu TZ; Huang YC; Huang LM
    Expert Rev Vaccines; 2009 Oct; 8(10):1317-27. PubMed ID: 19803753
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Recurrence of extensive injection site reactions following DTPa or dTpa vaccine in children 4-6 years old.
    Quinn P; Gold M; Royle J; Buttery J; Richmond P; McIntyre P; Wood N; Lee SS; Marshall H
    Vaccine; 2011 Jun; 29(25):4230-7. PubMed ID: 21497629
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immunogenicity of a triple diphtheria-tetanus-whole cell pertussis vaccine in Iranian preschool children.
    Zarei S; Jeddi-Tehrani M; Akhondi MM; Zeraati H; Kheirkhah T; Ghazanfari M; Shokri F
    Iran J Immunol; 2007 Jun; 4(2):101-9. PubMed ID: 17652850
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Injection site and risk of medically attended local reactions to acellular pertussis vaccine.
    Jackson LA; Yu O; Nelson JC; Dominguez C; Peterson D; Baxter R; Hambidge SJ; Naleway AL; Belongia EA; Nordin JD; Baggs J;
    Pediatrics; 2011 Mar; 127(3):e581-7. PubMed ID: 21300679
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Recommendation for an adolescent dose of tetanus and diphtheria toxoids and acellular pertussis vaccine: reassurance for the future.
    Halperin SA
    J Pediatr; 2006 Nov; 149(5):589-91. PubMed ID: 17095321
    [No Abstract]   [Full Text] [Related]  

  • 38. Concomitant use of the 3-dose oral pentavalent rotavirus vaccine with a 3-dose primary vaccination course of a diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated polio-Haemophilus influenzae type b vaccine: immunogenicity and reactogenicity.
    Ciarlet M; He S; Lai S; Petrecz M; Yuan G; Liu GF; Mikviman E; Heaton PM; Panzer F; Rose T; Koller DY; Van Damme P; Schödel F
    Pediatr Infect Dis J; 2009 Mar; 28(3):177-81. PubMed ID: 19209092
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Adverse events following booster doses of diphtheria-tetanus-inactivated poliovirus and acellular pertussis vaccines for 4-year-old children in The Netherlands.
    Bults M; Kemmeren JM; van der Maas NA
    Vaccine; 2007 Jul; 25(29):5272-7. PubMed ID: 17573165
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Safety and reactogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) when coadministered with routine childhood vaccines.
    Chevallier B; Vesikari T; Brzostek J; Knuf M; Bermal N; Aristegui J; Borys D; Cleerbout J; Lommel P; Schuerman L
    Pediatr Infect Dis J; 2009 Apr; 28(4 Suppl):S109-18. PubMed ID: 19325447
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.